Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Agios Pharmaceuticals, Inc. (AGIO : NSDQ)
 
 • Company Description   
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

Number of Employees: 488

 
 • Price / Volume Information   
Yesterday's Closing Price: $39.53 Daily Weekly Monthly
20 Day Moving Average: 562,615 shares
Shares Outstanding: 57.92 (millions)
Market Capitalization: $2,289.39 (millions)
Beta: 0.73
52 Week High: $62.58
52 Week Low: $23.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.58% 10.29%
12 Week 42.91% 20.21%
Year To Date 20.30% 12.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
88 SIDNEY STREET
-
CAMBRIDGE,MA 02139
USA
ph: 617-649-8600
fax: -
ir@agios.com http://www.agios.com
 
 • General Corporate Information   
Officers
Brian Goff - ChiefExecutiveOfficer
Jacqualyn A. Fouse - Chair of the Board of Directors
Cecilia Jones - Chief Financial Officer
T.J. Washburn - Vice President; Controller
Rahul Ballal - Director

Peer Information
Agios Pharmaceuticals, Inc. (CORR.)
Agios Pharmaceuticals, Inc. (RSPI)
Agios Pharmaceuticals, Inc. (CGXP)
Agios Pharmaceuticals, Inc. (BGEN)
Agios Pharmaceuticals, Inc. (GTBP)
Agios Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00847X104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 57.92
Most Recent Split Date: (:1)
Beta: 0.73
Market Capitalization: $2,289.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.87 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-7.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 6.71% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.56
Price/Cash Flow: -
Price / Sales: 61.82
EPS Growth
vs. Year Ago Period: -6.90%
vs. Previous Quarter: 10.92%
Sales Growth
vs. Year Ago Period: 6.56%
vs. Previous Quarter: -18.68%
ROE
06/30/25 - -
03/31/25 - -2.75
12/31/24 - -2.51
ROA
06/30/25 - -
03/31/25 - -2.52
12/31/24 - -2.26
Current Ratio
06/30/25 - -
03/31/25 - 18.50
12/31/24 - 11.90
Quick Ratio
06/30/25 - -
03/31/25 - 17.93
12/31/24 - 11.56
Operating Margin
06/30/25 - -
03/31/25 - -98.37
12/31/24 - -78.61
Net Margin
06/30/25 - -
03/31/25 - 1,798.26
12/31/24 - 1,845.92
Pre-Tax Margin
06/30/25 - -
03/31/25 - 1,917.72
12/31/24 - 1,967.15
Book Value
06/30/25 - -
03/31/25 - 25.32
12/31/24 - 27.02
Inventory Turnover
06/30/25 - -
03/31/25 - 0.17
12/31/24 - 0.16
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©